AKESO(09926),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

09926 AKESO

Not Yet Opened 10-12 16:08:17

107.200

-1.900

-1.74%

High111.000	Low107.100	Vol5.19M
Open110.900	D1 Closing109.100	Amplitude3.57%
Mkt Cap98.73B	Tradable Cap98.73B	Total Shares921.00M
T/O563.12M	T/O Rate0.56%	Tradable Shares921.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"09926","market":"HK","secType":"STK","nameCN":"AKESO","latestPrice":107.2,"timestamp":1791792497009,"preClose":109.1,"halted":0,"volume":5189891,"delay":0,"changeRate":-0.017415215398716696,"floatShares":921000000,"shares":921000000,"eps":-1.232771,"marketStatus":"Not Yet Opened","change":-1.9,"latestTime":"10-12 16:08:17","open":110.9,"high":111,"low":107.1,"amount":563120757,"amplitude":0.035747,"askPrice":107.2,"askSize":147000,"bidPrice":107.1,"bidSize":3000,"shortable":3,"etf":0,"ttmEps":-1.220827,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1791855000000},"marketStatusCode":0,"adr":0,"listingDate":1587657600000,"exchange":"SEHK","adjPreClose":109.1,"openAndCloseTimeList":[[1791768600000,1791777600000],[1791781200000,1791792000000]],"volumeRatio":0.8460551564765266,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"AKS.HK","impliedVol":0.6836,"impliedVolPercentile":0.65},"requestUrl":"/m/hq/s/09926/tweets","defaultTab":"tweets","newsList":[{"id":"2674806848","title":"Should Phase III Colon Cancer Trial Require Action From Akeso (SEHK:9926) Investors?","url":"https://stock-news.laohu8.com/highlight/detail?id=2674806848","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674806848?lang=en_us&edition=fundamental","pubTime":"2026-10-12 19:27","pubTimestamp":1791804462,"startTime":"0","endTime":"0","summary":"Akeso reported that the first patient has been dosed in a Phase III trial of cadonilimab as perioperative monotherapy for resectable MSI-H/dMMR colon cancer, expanding the antibody's evaluation beyond gastric, lung, and cervical indications.\nThe move into perioperative colon cancer targets an area where conventional chemotherapy delivers around 7% pathological response rates. If outcomes are positive, this could influence how Akeso allocates R&D and commercial resources around...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/should-phase-iii-colon-cancer-trial-require-action-from-akes","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/should-phase-iii-colon-cancer-trial-require-action-from-akes","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2399975544.HKD","BK1161","IE00BPRC5H50.USD","LU2476274308.USD","LU0348827113.USD","LU0417516902.SGD","LU0540923850.HKD","LU1961090484.USD","LU2488822045.USD","KURE","09926","LU1720050803.USD","LU0417516738.SGD","LU0561508036.HKD","LU2476274720.SGD","BK4211","LU0348766576.USD","LU2778985437.USD","LU0417516571.SGD","LU0348767384.USD","BK1574","ISBC","LU0348735423.USD","IE00B5MMRT66.SGD","LU0348784397.USD","LU1794554557.SGD","LU0348825331.USD","LU0634319403.HKD","IE00B543WZ88.USD","LU0348783233.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674164688","title":"Is Akeso (SEHK:9926) Cheap As Its Phase III Colon Cancer Trial Expands Its Pipeline?","url":"https://stock-news.laohu8.com/highlight/detail?id=2674164688","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674164688?lang=en_us&edition=fundamental","pubTime":"2026-10-11 08:30","pubTimestamp":1791678653,"startTime":"0","endTime":"0","summary":"Why this Phase III move matters for Akeso stock\nAkeso (SEHK:9926) has kicked off a Phase III trial of cadonilimab in resectable MSI-H/dMMR colon cancer, marking a new indication that could reshape expectations for its immuno-oncology portfolio.\nAkeso shares have picked up momentum in recent months, with a 16.56% 1 month share price return and 12.19% 3 month share price return at a last close of HK$109.1. However, the 1 year total shareholder return declined 14.77%, even as the 3 year total...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/is-akeso-sehk9926-cheap-as-its-phase-iii-colon-cancer-trial","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/is-akeso-sehk9926-cheap-as-its-phase-iii-colon-cancer-trial","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0417516738.SGD","LU0348766576.USD","LU0417516902.SGD","LU2778985437.USD","IE00B543WZ88.USD","LU1961090484.USD","LU0561508036.HKD","IE00BPRC5H50.USD","LU2476274308.USD","IE00B5MMRT66.SGD","LU0417516571.SGD","LU2476274720.SGD","LU0348783233.USD","LU0540923850.HKD","LU0348767384.USD","BK1161","LU0348735423.USD","LU2488822045.USD","LU0348784397.USD","LU0348825331.USD","LU0348827113.USD","LU2399975544.HKD","09926","LU0634319403.HKD","BK1574","LU1720050803.USD","LU1794554557.SGD","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674895664","title":"Akeso Doses First Patient in Phase III Cadonilimab Perioperative Trial for MSI-H/dMMR Colon Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2674895664","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674895664?lang=en_us&edition=fundamental","pubTime":"2026-10-10 12:41","pubTimestamp":1791607307,"startTime":"0","endTime":"0","summary":"Akeso doses first patient in Phase III cadonilimab perioperative trial for MSI-H/dMMR colon cancerAkeso dosed the first patient in a Phase III perioperative trial of cadonilimab for resectable MSI-H o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261010:nNDL6m5sjr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2476274308.USD","LU0540923850.HKD","LU0561508036.HKD","LU1720050803.USD","LU1961090484.USD","LU0348767384.USD","LU2399975544.HKD","LU2778985437.USD","LU0348735423.USD","LU0417516738.SGD","BK1161","IE00B543WZ88.USD","BK1574","LU0417516571.SGD","LU0348766576.USD","KURE","LU2488822045.USD","LU2476274720.SGD","LU0634319403.HKD","IE00B5MMRT66.SGD","LU0348784397.USD","LU1794554557.SGD","IE00BPRC5H50.USD","09926","LU0348825331.USD","LU0348827113.USD","LU0417516902.SGD","LU0348783233.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123515807","title":"Movement Alert｜AKESO Rises 4.26% in Regular Trading, ESMO Conference Catalyzes Innovative Drug Valuation","url":"https://stock-news.laohu8.com/highlight/detail?id=1123515807","media":"Market Focus","labels":["productRelease","conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123515807?lang=en_us&edition=fundamental","pubTime":"2026-10-09 14:44","pubTimestamp":1791528254,"startTime":"0","endTime":"0","summary":"On October 9, AKESO rose 4.26% in regular trading, trading at HK$110.0/share, with Turnover of HK$892 million.The ESMO 2026 Annual Meeting will be held from October 23 to 27. Chinese innovative drug...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"AKESO Jumps as ESMO Presidential Symposium Spotlights Key Data","news_tag":"productRelease,conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184790977","title":"Movement Alert｜AKESO Intraday Decline 3.02%, Biotechnology Sector Profit-Taking Drags Innovative Drug Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=1184790977","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184790977?lang=en_us&edition=fundamental","pubTime":"2026-10-08 13:52","pubTimestamp":1791438737,"startTime":"0","endTime":"0","summary":"On October 8, AKESO fell 3.02% in regular trading to HK$105.5, with turnover of HK$872 million. The decline came as the biotechnology sector extended its previous session's pullback, with short-term...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"AKESO Slides on Biotech Profit-Taking After AstraZeneca Deal","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176197277","title":"Akeso Leaves Share Count Unchanged in September 2026; 10.81 Million Options Outstanding","url":"https://stock-news.laohu8.com/highlight/detail?id=1176197277","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176197277?lang=en_us&edition=fundamental","pubTime":"2026-10-07 17:44","pubTimestamp":1791366240,"startTime":"0","endTime":"0","summary":"Akeso, Inc. (HKEX: 09926) filed its Monthly Return for the period ended 30 September 2026, indicating no changes in either authorised or issued share capital during the month. • Authorised capital...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168891186","title":"Movement Alert｜AKESO Falls 3.16% in Regular Trading, Biotech Sector Selloff Dragging Down Innovative Drug Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=1168891186","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168891186?lang=en_us&edition=fundamental","pubTime":"2026-10-07 09:47","pubTimestamp":1791337675,"startTime":"0","endTime":"0","summary":"On October 7, AKESO fell 3.16% in regular trading, trading at HK$107.1, with Turnover of HK$84.48 million. The decline was driven by a broad-based pullback across the biotechnology sector, as...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Biotech Selloff Drags AKESO Lower as Sector Retreats","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125673946","title":"Hong Kong Stock Movers: Innovative Drug Stocks Extend Gains as BofA Points to Three Major Recent Partnerships Strengthening Sector Momentum and ESMO Set to Bring Dense Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=1125673946","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125673946?lang=en_us&edition=fundamental","pubTime":"2026-10-06 10:10","pubTimestamp":1791252615,"startTime":"0","endTime":"0","summary":"According to a report, innovative drug concept stocks extended their gains. As of press time, CANSINOBIO (06185) rose 12.75% to HK$40.14; ASCLETIS-B (01672) gained 9.39% to HK$8.915; SBP GROUP...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185","01177","LNGR","BK4588","LU2476274308.USD","IE00BZ08YS42.EUR","LU0348783233.USD","06978","BK1574","LU1961090484.USD","LU2778985437.USD","LU0417516902.SGD","LU0417516571.SGD","LU0348766576.USD","VXUS","LU0348767384.USD","LU1794554557.SGD","LU0540923850.HKD","BK4585","HK0000165453.HKD","01672","BK1161","MEDX","IBBQ","BK1191","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","LU1720050803.USD","159992","BK1589","LU0348825331.USD","09926","KURE","IE00B5MMRT66.SGD","LU2476274720.SGD","LU0348827113.USD","LU0561508036.HKD","LU0634319403.HKD","LU0348735423.USD","KCAI","BK1521","IE00BPRC5H50.USD","LU0348784397.USD","LU2488822045.USD","LU2399975544.HKD","IE00B543WZ88.USD","BK1515","LU0417516738.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144564942","title":"Movement Alert｜AKESO Rises 3.3% in Regular Trading, Ivonescimab Global Combination Therapy Advances","url":"https://stock-news.laohu8.com/highlight/detail?id=1144564942","media":"Market Focus","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144564942?lang=en_us&edition=fundamental","pubTime":"2026-10-06 09:44","pubTimestamp":1791251082,"startTime":"0","endTime":"0","summary":"On October 6, AKESO rose 3.3% in regular trading, trading at HKD 109.7 per share, with a turnover of HKD 45.64 million.The movement follows news of AKESO's overseas partner entering a global joint...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"AKESO Rises as Ivonescimab Global Phase III Trial Advances","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672715686","title":"Major Drugmakers Turn to China for Licensing Deals","url":"https://stock-news.laohu8.com/highlight/detail?id=2672715686","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672715686?lang=en_us&edition=fundamental","pubTime":"2026-10-02 17:50","pubTimestamp":1790934645,"startTime":"0","endTime":"0","summary":"FACTBOX-Major drugmakers turn to China for licensing dealsOct 2 (Reuters)-Abogen said on Friday it has signed a licensing deal worth up to $7.8 billion with Swiss drugmaker NovartisNOVN.Sto develop an","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nL4N45O0HV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0106261372.USD","ILDR","688331","LU2023250843.SGD","IE0034235071.USD","LU1355424745.HKD","ELIS","BBH","LU0174119429.USD","01276","LU0061475181.USD","CURE","IE00BKPKM429.USD","LU0390134368.USD","LU1496350171.SGD","IE00BDGV0183.EUR","SG9999014880.SGD","IE00B7KXQ091.USD","LU0114720955.EUR","PAWZ","LU2211815571.USD","IE00BZ08YS42.EUR","LU0211327993.USD","LU0405327494.USD","BK1574","LU2491049909.HKD","BK0012","BK4578","LU1400636657.SGD","LU1051770623.HKD","IE0000B7K699.USD","LU1720051017.SGD","PFE","IE00BJJMRY28.SGD","LU0499090636.EUR","BK0183","LU0395794307.EUR","SG9999003800.SGD","LU0256863902.USD","LU1868836757.USD","IE00BJJMRX11.SGD","LU0463099449.HKD","BK0060","LU0787776722.HKD","LU1236620834.HKD","LU1894683264.USD","LU2596442595.SGD","LU0265550946.USD","LU0323591593.USD","LU0784383803.USD","LU0472753341.HKD","LU0557290698.USD","LLYX","LU0128525689.USD","LLYZ","LU0880133367.SGD","LU1046234339.USD","LU1226287875.USD","LU2114397693.USD","LU2237443465.HKD","LU1019634622.SGD","IE00BN8TJ469.HKD","LU2471134523.USD","IE0004445015.USD","LU0823434740.USD","LU0823434583.USD","LU0057025933.USD","LU0320765059.SGD","LU2237438978.USD","LU2580892862.HKD","LU2125154935.USD","LU1997244956.HKD","CANC","IE0008369823.USD","LU0306806265.USD","LU2242652126.USD","LU2361045086.USD","SG9999015358.SGD","LU0827474353.SGD","LU0053666078.USD","BNTX","LU0405327148.USD","LU0960981461.USD","LU1997245094.SGD","NVOH","LU0158827781.USD","LU0345777659.USD","LU2097828714.EUR","LU1255011170.USD","BK4592","IE00BZ1G4Q59.USD","LU1960683339.HKD","HRTS","SG9999017495.SGD","LU0348767384.USD","LU0502904849.HKD","LU0314109678.HKD","IE00B19Z3581.USD","LU1201861249.SGD","LU1781817850.SGD","REGN","LU0348783233.USD","SG9999015978.USD","LU1670711123.USD","LU2646069778.SGD","GSK.UK","SG9999018857.SGD","LU1868836914.USD","LU0889566641.SGD","LU2539964713.USD","LU1988902786.USD","LU0708994859.HKD","LU0471298777.SGD","LU1145028129.USD","LU0887340254.USD","LU0208291251.USD","LU1244550577.SGD","LU2168563687.JPY","LU0128525929.USD","LU0203202063.USD","LU0170899867.USD","LU1069344957.HKD","LU2328871848.SGD","LU0047473722.EUR","LU0094547139.USD","LU2148510915.USD","LU0882574139.USD","LU2237443549.SGD","SG9999015945.SGD","LU0417516902.SGD","LU0070302665.USD","LU0466842654.USD","IE00BJJMRZ35.SGD","LU2039709279.SGD","LU2168564495.EUR","LU1969619763.USD","NVS","IE00BFSS7M15.SGD","RXL","IE00BLSP4452.SGD","IE00BQJZX424.USD","LU0079474960.USD","LU0237698245.USD","IE00BFSS8Q28.SGD","LU1328277881.USD","LU0225284248.USD","LU0971552830.HKD","IE00BPRC5H50.USD","IE00BWXC8680.SGD","LU1974910355.USD","ABBV","LU0540923850.HKD","LU1997245177.USD","LU0171293334.USD","IE00B4R5TH58.HKD","IE00BKPKM643.USD","LU0708995401.HKD","LU2168564222.USD","LU0133085943.USD","SMMT","LU1267930573.SGD","PPH","IBB","IE00BJT1NW94.SGD","LU0052756011.USD","LU1551013425.SGD","LU2462157665.USD","LU0348766576.USD","IE0002270589.USD","LU1309081286.SGD","LU2361044949.HKD","LU0320765489.SGD","LLII","LU1941712264.USD","SG9999015986.USD","LU0385154629.USD","LU1699723380.USD","LU0640476718.USD","LU2097828474.EUR","BMY","LU0244354667.USD","LU2089284900.SGD","SG9999018865.SGD","LU0289739343.SGD","BK4533","LU0162691827.USD","LU0203345920.USD","LU1003076772.USD","LLY","LU1226287792.SGD","LU1804176565.USD","LU1228905540.USD","LU0689626769.HKD","LU0306807586.USD","LU0861579265.USD","LU2289578879.USD","LU0109391861.USD","LU2129689514.USD","IXJ","WDNA","LU0348827113.USD","LU1951186391.HKD","BK4550","BK4599","LU1064131342.USD","LU2433249047.HKD","LU2491050154.USD","03692","IBBQ","LU0072461881.USD","LU2129689431.USD","LU1366192091.USD","LU1863844665.USD","LU1839511570.USD","LU0969580561.USD","LU0784385840.USD","LU1712237335.SGD","LU1098665638.USD","LU2125909247.SGD","LU0345770308.USD","LU1093756325.SGD","LU0256863811.USD","LU0058720904.USD","LU0971552673.USD","LU0067412154.USD","LU2237443382.USD","SG9999001176.USD","SG9999015341.SGD","SGXZ99366536.SGD","LU0964807845.USD","LU0203347892.USD","MRK","LU0109394709.USD","LU2125154778.USD","LU0859254822.USD","IE00BZ08YR35.GBP","LU2023251221.USD","LU1035773651.USD","LU1328615791.USD","LU0757432116.USD","LU1670627923.USD","LU1064131003.USD","LU1008478684.HKD","BK0188","LU1301847155.USD","LU2028103732.USD","SG9999001176.SGD","FHLC","TRUH","LU1655091616.SGD","LU0158827948.USD","LU1074936037.SGD","LU2362541273.HKD","GLAM","SG9999004220.SGD","LU0130517989.USD","LU0477156953.USD","LU0792757196.USD","LU2468319806.SGD","LU0047473722.SGD","LU2063271972.USD","LU1645745479.HKD","LU0957799991.USD","LU1153584641.USD","600276","IE00B1XK9C88.USD","LU1732800096.USD","LU0417516571.SGD","SG9999014906.USD","LU2461242641.AUD","BK4568","LU0316494557.USD","NVO","BMED","PJP","LU1670710661.SGD","LU0726765562.USD","IE00BWDBJ516.SGD","IE00BVYPNW00.USD","LU1228905037.USD","LU0456855351.SGD","LU1066051225.USD","LU1481599808.USD","IE00BFXG1179.USD","LU1880407215.USD","LU1989771016.USD","IE00B775H168.HKD","LU3187612489.SGD","LU0321505868.SGD","LU0784385170.HKD","SG9999014914.USD","LU1430594728.SGD","BK4548","BK4551","LU1066051811.HKD","LU1718418525.SGD","LU2293690082.USD","LU1146622755.USD","LU0011850046.USD","LU1941712348.USD","LU1481600234.SGD","LU2417539215.USD","LU2750360641.GBP","IE00BKVL7J92.USD","LU0965508806.USD","BK4581","LU2087625088.SGD","IE00BJLML261.HKD","JDOC","LU1084165304.USD","LU2265009873.SGD","BK4007","LU2324357040.USD","LU0315179316.USD","BK0239","IE00BKDWB100.SGD","LU0006306889.USD","HK0000165453.HKD","LU2097828557.USD","LU2471134879.HKD","LU0661504455.SGD","LU1267930227.SGD","LU0289961442.SGD","LU0987226296.USD","LU0920783379.SGD","LU2357305700.SGD","IE00BGHQF631.EUR","BK1593","BK1191","LU0266013472.USD","LU2089984988.USD","LU2213496289.HKD","BK4139","03933","LU2237443978.SGD","BK4534","LU0561508036.HKD","IE00BFTCPJ56.SGD","BK1161","LU1691799644.USD","LU1720051108.HKD","MEDX","IE000M9KFDE8.USD","SGXZ51526630.SGD","LU0889565916.HKD","IE00B19Z3B42.SGD","KURE","LU2756315318.SGD","LU0320765992.SGD","BK5011","IE00B3T34201.USD","LU1814569148.SGD","LU2347655073.USD","LU0575583348.USD","LU0122379950.USD","LU0310799852.SGD","LU0211328371.USD","LU1989772923.USD","LU2125909593.SGD","IE000F7OJYX1.SGD","LU0265550359.USD","BK1515","LU0823399737.USD","OZEM","LU0321505439.SGD","LU2355687059.USD","SG9999014575.USD","LU0353189763.USD","LU2097828631.EUR","LU0648001328.SGD","LU0326950275.SGD","LU0882574055.USD","LU1069347547.HKD","LU1064927863.SGD","LU0098860793.USD","LU0820561818.USD","LU0072913022.USD","LU2471134952.CNY","LU1993786604.SGD","LU1983299246.USD","LU1152091754.HKD","LU0965509283.SGD","LU0672654240.SGD","LU1267930730.SGD","LU1720050803.USD","LU1032466523.USD","LU0348825331.USD","LU2471134796.USD","LU1170363599.USD","IE00BVYPNV92.GBP","SGXZ31699556.SGD","LU1732799900.SGD","LU2168564065.EUR","LU1829250122.USD","LU1116320737.USD","SG9999002224.SGD","LU0345770993.USD","LU0353189680.USD","IE000MB6IJN5.SGD","LU0097036916.USD","SG9999002232.USD","02096","LU0198837287.USD","BK4585","LU1487256676.USD","LU0432979614.USD","IE00B3PB1722.GBP","LU1302929846.USD","LU0689472784.USD","BK1583","IE00BBT3K403.USD","LU0211326755.USD","LU2279689827.SGD","AZN.UK","BK4532","LU2111349929.HKD","LU0238689110.USD","LU1236620750.USD","LU1883839398.USD","01093","LU0964806797.USD","LU1153585028.USD","LU2746668461.USD","LU1162221912.USD","LU1323610961.USD","SGXZ81514606.USD","LU1019632923.USD","LU0997586432.USD","LU1894683348.USD","LU0345777147.USD","LU0820561909.HKD","BK4559","LU0868494708.USD","LU0868494617.USD","LU1061106388.HKD","LU2488822045.USD","IE00BLSP4239.USD","LU1820825898.SGD","LU0980610538.SGD","ELIL","LU0320765646.SGD","LU0965509101.SGD","LU1629891620.HKD","LU0943347566.SGD","IE00BN29S564.USD","LU2271345857.HKD","LU2361044865.SGD","LU1188198961.HKD","LU0526926950.USD","LU2023250504.SGD","LU0997586515.USD","LU0130102774.USD","IE0002141913.USD","LU0455707207.USD","LU0795875086.SGD","IE0009355771.USD","LU2023250330.USD","LU1037948541.HKD","GB00BDT5M118.USD","LU0823416689.USD","LU1057294990.SGD","LU1979441026.SGD","LU0545562505.USD","LU1813983027.USD","SG9999014542.SGD","LU1037948897.HKD","GDOC","LU1015430645.USD","LU1868837136.USD","LU0501845795.SGD","XLV","LU1093756168.USD","LU0161305163.EUR","LU1226287529.USD","LU1116320901.HKD","BK4535","LU1807302812.USD","BK0028","LU1003077747.HKD","LU1917777945.USD","LU2347655156.SGD","LU0607220059.USD","LU1291159041.SGD","LU2495084118.USD","LU0348735423.USD","LU0211331839.USD","LU1934455277.USD","LU2360106947.USD","LU0965509010.AUD","LU2896262040.SGD","LU0140636845.USD","LU0963555726.SGD","IE00B42XCP33.USD","LU1267930813.SGD","LU1104425308.USD","LU0784384876.USD","LU0225283273.USD","LU1232071149.USD","LU1929549753.HKD","LU1267930490.SGD","IE000SO60NU8.SGD","MEDI","LU2264538146.SGD","FTXH","LU1868837300.USD","LU0920840948.USD","LU0234570918.USD","IE00BK4W5L77.USD","LU0354030438.USD","LU1623119135.USD","MHIP","IHE","LU0795875169.SGD","IE00BK4W5M84.HKD","LU1670711040.USD","LU2456880835.USD","LU1670710588.SGD","LU0683600562.USD","BK0196","BK1588","LU2462591350.SGD","LU0234572021.USD","LU1868836591.USD","SG9999011175.SGD","LU1244550494.USD","LU1400636491.USD","LU2106854487.HKD","NVOC","LU0069063385.USD","IYH","IE000BZT7R73.USD","LU2242644610.SGD","LU2112291526.USD","LU0267386448.USD","LU0149534421.HKD","LU1046248800.SGD","LU2778985437.USD","LU2089283258.USD","LU1244550221.USD","LU2491050071.SGD","RHHBY","LU1226288253.USD","LU0949170426.SGD","IE00B1BXHZ80.USD","LU1202635105.USD","BK4588","LU0949170772.SGD","LU1831875114.USD","LU1571399168.USD","LU2129689605.HKD","LU1880407132.USD","LU0738911758.USD","LU1064130708.USD","SG9999001440.SGD","IE00B031HY20.USD","LU2756315664.SGD","LU2476274308.USD","LU1863844749.USD","09995","LU1670628061.USD","LU1934455194.USD","LU0210536198.USD","LU2552382058.USD","LU1261432733.SGD","LU0310800965.SGD","LU1066051498.USD","LU1670756490.USD","LU2091194634.USD","HCM","LU0077335932.USD","LU2602419157.SGD","LU0096364046.USD","IE0034235188.USD","LU0289739699.SGD","LU0942090050.USD","LU1023059063.AUD","BK4516","IE0008368742.USD","LU2362541513.USD","09926","LU0154236417.USD","LU0985481810.HKD","LU2168564149.EUR","03165","LU1035777561.USD","LU1226288170.HKD","LU0225771236.USD","LU0985320562.USD","BK1521","LU2552382215.SGD","LU0976567544.SGD","TMED","IE00B2B36J28.USD","LU0496365809.HKD","LU0348784397.USD","BK1587","LU0889565080.SGD","SG9999014898.SGD","LU0171276677.USD","LU2087621335.USD","BK4566","LU0029864427.USD","LU0417517546.SGD","VHT","BK1589","LU0109981661.USD","LU2476274720.SGD","AGNG","LU2237443622.USD","LU1585245621.USD","LU2108987350.USD","LU0857590862.USD","NVOX","LU1794554557.SGD","IE00BSNM7G36.USD","LU1400636574.HKD","SG9999015952.SGD","LU2362540622.SGD","LU1066053197.SGD","SG9999014559.SGD","IE00B543WZ88.USD","LU0545039389.USD","LU1580142542.USD","LU2552382132.HKD","SGXZ57979304.SGD","IE000WAW04H5.SGD","LU1196032939.SGD","IE00B5MMRT66.SGD","IE00B4JS1V06.HKD","LU1496350502.SGD","LU0471298694.HKD","LU1127390331.HKD","IE00B3M56506.USD","LU1280957306.USD","LU1035775433.USD","SG9999014567.USD","LU2399975544.HKD","TBXU","IE0005OL40V9.USD","LU0553294199.USD","LU0912757837.SGD","LU1923622614.USD","LU0972486137.USD","LU2133065610.SGD","LU1273509221.SGD","LU0634319403.HKD","LU2746668974.SGD","LU1078025761.USD","LU2750360997.AUD","LU1548497426.USD","LU0786609619.USD","IE0004445239.USD","LU0354030511.USD","688506","LU2360032135.SGD","LU0511384066.AUD","IE00BZ08YT58.USD","LU0310800379.SGD","00013","LU0124676726.USD","SG9999013999.USD","LU2580892789.USD","01530","LU2293690249.USD","LU1152091168.USD","LU1119994496.HKD","LU0203201768.USD","LU2236285917.USD","LU0640478417.SGD","LU0820562030.AUD","LU0417516738.SGD","LU1961090484.USD","LU2357627491.SGD","01801","LU1989772840.SGD","THNR","LU1934455863.HKD","LU2237443895.HKD","LU1551013342.USD","LU2242646821.SGD","LU2097828805.USD","IE0001KFT4U8.USD","LU0211326839.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672271376","title":"Akeso (SEHK:9926) Could Be 31% Undervalued As Phase III Trial Hits Key Goals","url":"https://stock-news.laohu8.com/highlight/detail?id=2672271376","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672271376?lang=en_us&edition=fundamental","pubTime":"2026-10-02 15:18","pubTimestamp":1790925532,"startTime":"0","endTime":"0","summary":"Akeso (SEHK:9926) just put fresh clinical data at the center of its story. The company reported that its Phase III HARMONi-GI1 trial for advanced biliary tract cancer hit key survival goals.\nAkeso shares have reacted quickly to the HARMONi-GI1 headlines, with a 1-day share price return of 2.26% and a 7-day move of 15.76%. This has built on a 30-day gain of 26.91%, yet the shares are still sitting on a year-to-date share price decline of 4.06% and a 1-year total shareholder return down 22.25%...","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-sehk9926-could-be-31-undervalued-as-phase-iii-trial-hi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-sehk9926-could-be-31-undervalued-as-phase-iii-trial-hi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0348735423.USD","LU2488822045.USD","LU2778985437.USD","LU0417516571.SGD","LU0561508036.HKD","LU1794554557.SGD","LU0634319403.HKD","LU1961090484.USD","LU0348784397.USD","LU0348767384.USD","KURE","LU0348783233.USD","LU2399975544.HKD","BK1161","LU0348766576.USD","LU0348827113.USD","LU2476274308.USD","LU0417516902.SGD","LU0540923850.HKD","09926","LU0417516738.SGD","LU1720050803.USD","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","IE00B543WZ88.USD","LU2476274720.SGD","LU0348825331.USD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106342677","title":"Movement Alert｜AKESO Falls 3.59% in Regular Trading, Biotech Sector Broadly Weak as Post-Rally Profit-Taking Continues","url":"https://stock-news.laohu8.com/highlight/detail?id=1106342677","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106342677?lang=en_us&edition=fundamental","pubTime":"2026-10-02 09:52","pubTimestamp":1790905932,"startTime":"0","endTime":"0","summary":"On October 2, AKESO declined 3.59% in regular trading to HK$104.2, with turnover of HK$137 million. The stock pulled back further following a sharp rally late last week driven by AstraZeneca's US$2...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"AKESO Drops as Biotech Sector Faces Broad Profit-Taking","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671051201","title":"Major Drugmakers Turn to China for Licensing Deals","url":"https://stock-news.laohu8.com/highlight/detail?id=2671051201","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671051201?lang=en_us&edition=fundamental","pubTime":"2026-09-30 20:17","pubTimestamp":1790770671,"startTime":"0","endTime":"0","summary":"FACTBOX-Major drugmakers turn to China for licensing dealsSept 30 (Reuters)-Novo NordiskNOVOb.COsaid on Tuesday it will pay up to$2.6 billionto Jiangsu Hengrui Pharmaceuticals600276.SSfor the rights t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nL4N45M0T3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WDNA","LLYX","GDOC","01801","MRK","TRUH","THNR","MEDI","TMED","AGNG","600276","LLYZ","RXL","OZEM","09926","VHT","FTXH","BMED","KURE","IYH","CGNX","IHE","PFE","HRTS","IXJ","LLY","MEDX","ILDR","00013","PJP","PAWZ","688331","ELIS","CURE","ELIL","RSHO","PPH","BNTX","03692","JDOC","LLII","SMMT","GSK.UK","FHLC","GLAM","XLV","01530","CANC","ABBV","MHIP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672384227","title":"Should Phase III Cancer Trial Win Require Action From Akeso Stock Investors?","url":"https://stock-news.laohu8.com/highlight/detail?id=2672384227","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672384227?lang=en_us&edition=fundamental","pubTime":"2026-09-30 17:20","pubTimestamp":1790760033,"startTime":"0","endTime":"0","summary":"Akeso reported that its bispecific antibody ivonescimab achieved statistically significant and clinically meaningful superiority in overall survival, progression free survival, and objective response rate versus a durvalumab based regimen in the Phase III HARMONi-GI1 biliary tract cancer trial, with full data selected for a Presidential Symposium at ESMO 2026.\nThe cluster of nearly 30 ESMO 2026 presentations on ivonescimab, cadonilimab, and early ADC assets, plus fresh Phase I clearance for...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/should-phase-iii-cancer-trial-win-require-action-from-akeso","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/should-phase-iii-cancer-trial-win-require-action-from-akeso","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0348767384.USD","LU2488822045.USD","LU0348827113.USD","LU0561508036.HKD","LU2476274308.USD","LU0417516738.SGD","LU2778985437.USD","LU1961090484.USD","IE00BPRC5H50.USD","LU0634319403.HKD","09926","ISBC","LU1720050803.USD","LU0348784397.USD","BK1161","KURE","LU0417516571.SGD","IE00B5MMRT66.SGD","LU0348783233.USD","LU0540923850.HKD","LU0348766576.USD","BK4211","LU1794554557.SGD","BK1574","IE00B543WZ88.USD","LU0348825331.USD","LU0348735423.USD","LU2476274720.SGD","LU2399975544.HKD","LU0417516902.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120927837","title":"Daiwa: Akeso's Global Partner Summit Secures AstraZeneca Investment, Boosting Ivonescimab's Global Peak Sales Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=1120927837","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120927837?lang=en_us&edition=fundamental","pubTime":"2026-09-30 15:00","pubTimestamp":1790751620,"startTime":"0","endTime":"0","summary":"According to a research report from Daiwa, a \"Buy\" rating has been assigned to Akeso (09926).Akeso's global partner Summit (SMMT.US) announced on the evening of Monday (the 28th) US Eastern Time that...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417516738.SGD","LU0348766576.USD","LU0417516902.SGD","LU2778985437.USD","IE00B543WZ88.USD","LU1961090484.USD","LU0561508036.HKD","IE00BPRC5H50.USD","LU2476274308.USD","IE00B5MMRT66.SGD","LU0417516571.SGD","LU2476274720.SGD","LU0348783233.USD","LU0540923850.HKD","LU0348767384.USD","BK1161","LU0348735423.USD","LU2488822045.USD","LU0348784397.USD","LU0348825331.USD","LU0348827113.USD","LU2399975544.HKD","09926","LU0634319403.HKD","BK1574","LU1720050803.USD","LU1794554557.SGD","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172902077","title":"Nomura Assigns HK$138.29 Target Price and \"Buy\" Rating to Akeso","url":"https://stock-news.laohu8.com/highlight/detail?id=1172902077","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172902077?lang=en_us&edition=fundamental","pubTime":"2026-09-30 15:00","pubTimestamp":1790751617,"startTime":"0","endTime":"0","summary":"Nomura has issued a research report assigning a target price of HK$138.29 and a \"Buy\" rating to Akeso (09926).Nomura noted that before the Hong Kong stock market opened on September 29, Akeso and its...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1961090484.USD","02157","09926","LU0348735423.USD","LU0634319403.HKD","KURE","LU2488822045.USD","BK1574","IE00B5MMRT66.SGD","LU0348783233.USD","LU0348784397.USD","LU0561508036.HKD","LU0348766576.USD","LU0417516902.SGD","LU2476274308.USD","BK1583","IE00BPRC5H50.USD","LU1794554557.SGD","LU0348825331.USD","LU0417516571.SGD","02162","LU2778985437.USD","BK1161","LU0417516738.SGD","EWH","LU2476274720.SGD","IE00B543WZ88.USD","BK1587","LU0348767384.USD","LU1720050803.USD","LU2399975544.HKD","LU0348827113.USD","LU0540923850.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180811634","title":"Movement Alert｜AKESO Falls 3.86% in Regular Trading, Profit-Taking After Previous Session Surge of Over 15% on AstraZeneca-Summit Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=1180811634","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180811634?lang=en_us&edition=fundamental","pubTime":"2026-09-30 09:31","pubTimestamp":1790731912,"startTime":"0","endTime":"0","summary":"On September 30, AKESO fell 3.86% in regular trading, trading at 102.7 HKD/share, with turnover of 169 million HKD. The decline came as investors locked in gains following the stock's 15.54% surge in...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"AKESO Slides on Profit-Taking After AstraZeneca-Summit Boost","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173705860","title":"Hong Kong Stock Connect Innovative Drug Sector Defies Market Downturn as Top Pharmaceutical Firm Enters with US$2 Billion, Akeso Surges 15.54%, Hengrui Pharma Secures US$2.6 Billion BD Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=1173705860","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173705860?lang=en_us&edition=fundamental","pubTime":"2026-09-29 19:20","pubTimestamp":1790680850,"startTime":"0","endTime":"0","summary":"On September 29, the Hong Kong stock market retreated, but innovative drugs led gains against the broader trend. The Hang Seng Stock Connect Innovative Drug ETF (520880) tracking index, with 100%...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1820825898.SGD","LU0348825331.USD","BK0028","BK0060","BK0196","LU1997245094.SGD","LU0417516738.SGD","LU1794554557.SGD","BK0012","BK1574","LU2778985437.USD","LU2148510915.USD","LU2543165471.USD","KURE","LU0348783233.USD","LU2399975544.HKD","LU0417516571.SGD","LU2476274720.SGD","LU0359202008.SGD","LU1255011170.USD","LU1146622755.USD","LU0348767384.USD","LU1328615791.USD","LU1969619763.USD","LU1023057109.AUD","LU2328871848.SGD","LU2495084118.USD","LU0359201885.HKD","06978","LU0348827113.USD","BK1191","01276","IE00BPRC5H50.USD","LU0540923850.HKD","LU0348766576.USD","LU2097828631.EUR","LU1997244956.HKD","IE00B543WZ88.USD","LU2097828805.USD","LU1580142542.USD","LU1064131003.USD","LU2097828714.EUR","MEDX","LU2476274308.USD","BK0188","LU2097828557.USD","LU0405327148.USD","LU2289578879.USD","09926","LU1720050803.USD","LU1961090484.USD","LU1064130708.USD","LU0359201612.USD","LU0405327494.USD","BK1161","600276","LU2097828474.EUR","LU2488822045.USD","LU1781817850.SGD","LU0417516902.SGD","LU0348784397.USD","LU0561508036.HKD","LU0634319403.HKD","BK0183","LNGR","LU1655091616.SGD","LU1997245177.USD","LU2580892789.USD","LU2580892862.HKD","FLHK","IE00B5MMRT66.SGD","159992","LU0348735423.USD","BK0239","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101404369","title":"Akeso, Inc. (09926): Yu Xia Acquires Shares, Long Position Rises to 25.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=1101404369","media":"HK Disclosure","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101404369?lang=en_us&edition=fundamental","pubTime":"2026-09-29 17:32","pubTimestamp":1790674364,"startTime":"0","endTime":"0","summary":"Yu Xia bought 100,000 shares of Akeso, Inc. on the SEHK open market at an average of HKD 94.0665 per share on June 15, 2026, involving about HKD 9.41 million, in an on-exchange active trade (direct...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183825958","title":"China A-Share Indices Reverse Early Gains as Real Estate Stocks Surge, Vanke Hits Limit Up, Biotech Rallies, Hang Seng Tech Falls Over 1%, New Energy Vehicle Shares Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=1183825958","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183825958?lang=en_us&edition=fundamental","pubTime":"2026-09-29 10:34","pubTimestamp":1790649241,"startTime":"0","endTime":"0","summary":"On September 29, A-share markets traded lower in morning session, with the three major indices collectively reversing early gains after an initial rally. The micro-cap stock index rebounded, the real...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03088","BK0183","BK4548","02837","LU2488822045.USD","LU1580142542.USD","LU0880133367.SGD","02202","BK0157","LU0708995583.HKD","03033","BK4099","IE00B5MMRT66.SGD","BK4532","LU1655091616.SGD","LU0067412154.USD","LU2476274308.USD","BK0273","LU1064131003.USD","LU0417516738.SGD","LU1064130708.USD","NIO","09866","IE00B543WZ88.USD","HSTECH","LU1807302812.USD","LU0417516902.SGD","BK4531","EVS.SI","NIO.SI","LU0634319403.HKD","LU0348735423.USD","BK1574","03032","BK0178","LU0072913022.USD","LU0348784397.USD","BK4504","BK4534","LU0540923850.HKD","LU2399975544.HKD","BK0174","BK0196","BK0180","BK0201","BK0278","BK4588","NIOG","LU0348766576.USD","03423","BK4555","07226","BK4509","LU0348783233.USD","BK0187","BK0028","LU0417516571.SGD","BK1161","000001","HSI","IE00BPRC5H50.USD","BK0188","LU0501845795.SGD","BK0086","LU1328615791.USD","LU2476274720.SGD","LU1794554557.SGD","LU1781817850.SGD","LU1226287529.USD","KURE","LU0348827113.USD","LU0052750758.USD","09067","LU1961090484.USD","09088","LU1720050803.USD","BK4574","BK4505","LU2778985437.USD","BK4526","03067","09926","03417","BK4585","LU0348825331.USD","LU0348767384.USD","HTImain","LU0320764599.SGD","07552","LU2148510915.USD","000002","BK0012","LU1993786604.SGD","LU0561508036.HKD","IE00B0JY6N72.USD","BK4581"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akesobio.com","stockEarnings":[{"period":"1week","weight":0.0113},{"period":"1month","weight":0.1872},{"period":"3month","weight":0.1184},{"period":"6month","weight":-0.2727},{"period":"1year","weight":-0.1625},{"period":"ytd","weight":-0.0513}],"compareEarnings":[{"period":"1week","weight":0.0096},{"period":"1month","weight":-0.0215},{"period":"3month","weight":-0.0029},{"period":"6month","weight":-0.0646},{"period":"1year","weight":-0.0768},{"period":"ytd","weight":-0.053}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Akeso Inc is an investment holding company dedicated to the research, development, manufacturing and commercialization of antibody drugs that are affordable to patients worldwide. The Company’s programs covering the therapeutic areas of oncology, autoimmune and metabolic diseases. The Company's products mainly include cadonilimab (PD-1/CTLA-4), ivonescimab (PD-1/VEGF), Ligufalimab (AK117, CD47), Pulocimab (AK109, VEGFR-2), ANNIKO (penpulimab, PD-1), and tagitanlimab (PD-L1) used in oncology fields as well as ebronucimab (PCSK9), ebdarokimab (IL-12/IL-23), and Gumokimab (AK111, IL-17) used in metabolic and autoimmune therapeutic fields.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.003338},{"month":2,"riseRate":0.333333,"avgChangeRate":0.019031},{"month":3,"riseRate":0.5,"avgChangeRate":0.006875},{"month":4,"riseRate":0.833333,"avgChangeRate":0.041517},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.021305},{"month":6,"riseRate":0.571429,"avgChangeRate":0.077852},{"month":7,"riseRate":0.571429,"avgChangeRate":0.084887},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.012805},{"month":9,"riseRate":0.571429,"avgChangeRate":0.060911},{"month":10,"riseRate":0.428571,"avgChangeRate":0.037482},{"month":11,"riseRate":1,"avgChangeRate":0.102206},{"month":12,"riseRate":0.333333,"avgChangeRate":0.028279}],"exchange":"SEHK","name":"AKESO","nameEN":"AKESO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"AKESO(09926),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest AKESO(09926) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"AKESO,09926,AKESO股票,AKESO股票老虎,AKESO股票老虎国际,AKESO行情,AKESO股票行情,AKESO股价,AKESO股市,AKESO股票价格,AKESO股票交易,AKESO股票购买,AKESO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"AKESO(09926),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest AKESO(09926) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}